Cervical Cancer Clinical Trials
Cervical cancer clinical trials are performed every day at Moffitt Cancer Center as we endeavor to discover new ways to treat cancer and enhance the lives of our patients. These promising studies are carefully designed in laboratories and then thoroughly tested in a multi-stage process before they are made available to the general public. At Moffitt, the health and safety of our patients always come first.
Joining a Cervical Cancer Clinical Trial at Moffitt
Patients who are interested in cervical cancer clinical trials are encouraged to consult with a physician at Moffitt. For the convenience of our patients, we do not require referrals for these or any other types of consultations. Our team can find out whether there is availability in a suitable clinical trial and, if so, determine a patient’s eligibility. To do so, we consider many factors, such as a patient’s age, type and stage of cancer, past treatments, general health and other conditions. In this way, we can help ensure an optimal match between patient and study.
Top 1% of Cancer Hospitals
Schedule an AppointmentIf a patient is qualified to participate in one of our cervical cancer clinical trials, the team at Moffitt will do everything possible to help her make an informed decision on whether to proceed. During a personal consultation, we will:
- Fully explain the proposed treatment
- Discuss the care the patient will receive, including the necessary tests and office visits
- Describe what the patient can expect to happen and how the treatment might affect her everyday life
- Provide details on the risks and benefits of participation
- Answer all questions
- Review the consent form
It is important for prospective clinical trial participants to understand that they are never required to take part in or complete a medical research study. We want each patient to be fully comfortable with her treatment decisions. Therefore, participants can opt-out of a clinical trial at any time – even after they have signed a consent form. If a patient chooses to leave an ongoing study, the team at Moffitt will discuss other available treatment options to ensure the best care possible.
Learn More
If you would like to know more about cervical cancer clinical trials at Moffitt Cancer Center, call 1-813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form online.
-
Clinical Trials
CLINICAL TRIAL 23143
Trends and Outcomes in HIV-positive Patients Undergoing Treatment for Invasive or Preinvasive Cervical and Other Gynecologic Neoplasias
Condition: Gynecological Tumor
Intervention:
CLINICAL TRIAL 23229
An Open-Label Phase 1/2a Clinical Trial to Evaluate the Safety, Immunogenicity, and Preliminary Efficacy of a Lentiviral Vector-Based Therapeutic Vaccine Against Human Papilloma Virus (Lenti-HPV-07) in Participants with HPV-Associated Oropharyngeal Squamous Cell Cancer or Cervical Cancer
Condition: Multiple
Intervention: Lenti-HPV-07 ()
CLINICAL TRIAL 23380
A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Autologous Logic-gated Tmod CAR T Protducts in Heterozygous HLA-A*02 Adult with Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Condition: Thoracic
Intervention: A2B543 (); A2B694 (); IL-2 (Interleukin-2); MESNA (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)
CLINICAL TRIAL 23618
Genomic and Immunological Roadmap of Archival HPV Gynecologic Malignancies in Diverse Populations
Condition: Gynecological Tumor
Intervention:
CLINICAL TRIAL 23549
A Phase 1/1b Study of VET3-TGI Administered Alone and in Combination with Atezolizumab in Patients with Advanced Solid Tumors
Condition: Thoracic
Intervention: Atezolizumab (Tecentriq); VET3-TGI ()
CLINICAL TRIAL 23645
A Phase 1 Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors
Condition: Multiple
Intervention: XB628 ()
CLINICAL TRIAL 23659
A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of ARV-806 in Participants With KRAS G12D Mutated Advanced Solid Tumors
Condition: Multiple
Intervention: ARV-806 ()
CLINICAL TRIAL 23697
A Phase 1/1b, Open-label, Multicenter, First-in-human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of VVD-159642, a RAS-PI3KA Inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Condition: Multiple
Intervention: AMG 510 (Sotorasib); GSK1120212 (Trametinib); Olomorasib (); Sotorasib (); Trametinib (); VVD-159642 ()